Assembly Biosciences, Inc.
NASDAQ:ASMBBiotechnology
+$0.16 today
- Market cap
- $460.74M
- Beta
- 1.08
- P/E (TTM)
- -64.4
- EPS (TTM)
- -$0.38
Volume 0.33M
Average 0.17M
Income Statement
Follow revenue through to earnings.
Revenue
$72.30M
FY 2025 · Annual
+153.5% YoYOperating Income
-$12.12M
FY 2025 · Annual
Net Income
-$6.12M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.25M | 0 | 7.16M | 28.52M | 72.3M |
| Cost of Revenue | 0 | 69.08M | 48.9M | 55.93M | 129K |
| Gross Profit | 6.25M | (69.08M) | (41.74M) | (27.41M) | 72.17M |
| Gross Margin | 100.0% | — | -582.7% | -96.1% | 99.8% |
| Research & Development | 68.52M | 69.98M | 48.9M | 55.93M | 64.81M |
| Selling, General & Admin | 28.78M | 23.93M | 22.91M | 18.01M | 19.61M |
| Operating Expenses | 138.94M | 25.03M | 22.91M | 18.01M | 84.42M |
| Depreciation & Amortization | 466K | 498K | 450K | 129K | 129K |
| EBITDA | (90.58M) | (92.52M) | (60.75M) | (39.72M) | (5.99M) |
| EBITDA Margin | -1448.4% | — | -848.0% | -139.3% | -8.3% |
| Operating Income | (132.69M) | (94.11M) | (64.65M) | (45.42M) | (12.12M) |
| Operating Margin | -2121.7% | — | -902.5% | -159.3% | -16.8% |
| Interest Income | 302K | 1.02M | 3.45M | 5.57M | 6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 302K | 1.02M | 3.45M | 5.57M | 6M |
| Income Before Tax | (132.39M) | (93.09M) | (61.2M) | (39.85M) | (6.12M) |
| Pre-Tax Margin | -2116.8% | — | -854.3% | -139.7% | -8.5% |
| Income Tax Expense | (2.53M) | 0 | 33K | 330K | 0 |
| Net Income | (129.86M) | (93.09M) | (61.23M) | (40.18M) | (6.12M) |
| Net Margin | -2076.4% | — | -854.8% | -140.9% | -8.5% |
| EPS (Basic) | (36.00) | (22.82) | (13.38) | (6.69) | (0.55) |
| EPS (Diluted) | (36.00) | (22.82) | (13.38) | (6.69) | (0.55) |
| 3.61M | 4.03M | 4.58M | 6M | 11.21M | |
| 3.61M | 4.03M | 4.58M | 6M | 11.21M |
ASMB Earnings Waterfall · TTM
NASDAQ:ASMB · Revenue to Net Income
Key Ratios
Analysis
$71.1M of revenue converted into -$6.4M of net income for the selected period. Gross margin is 58.0% and net margin is -62.4%, showing how much revenue survives after costs and taxes. EPS is $-0.58, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much revenue does ASMB generate?
Assembly Biosciences, Inc. (ASMB) reported $72.30M of revenue in fiscal 2025.
Is ASMB profitable?
Assembly Biosciences, Inc. (ASMB) reported -$6.12M of net income, with a net margin of -8.5%.
Continue the stock analysis
Jump to another research area for this company.